Novo Nordisk's injectable GLP-1RA sales set to rise with imminent label expansion, says analyst

Danish diabetes care giant Novo Nordisk (NOV: N) recently revealed that its FLOW trial, which studies Ozempic (semaglutide) in diabetic patients with chronic kidney disease (CKD), will come to a halt almost one year prior to the planned completion date, as interim results alone were sufficient in proving that the treatment was successful in treating kidney failure in this patient group.

However, Novo Nordisk will remain blinded to the data until the trial reaches its formal completion date. The company already has a strong presence in the type 2 diabetes (T2D) and obesity markets. Consequently, the results of Novo Nordisk’s promising FLOW trial may bolster the sales of its subcutaneous glucagon-like peptide-1 receptor agonist (GLP-1 RA) across these indications and other prospective treatment areas, says pharma analytics company GlobalData.

GlobalData’s latest report “ Obesity: Seven-Market Drug Forecast and Market Analysis”, which explores marketed and late-stage pipeline pharmacotherapies in the obesity space, reveals that in the USA, Wegovy (semaglutide - indicated for obesity), and Ozempic (semaglutide - indicated for T2D and prescribed off-label for obesity) are forecast to reach sales of $8.1 billion and $2.1 billion by 2031, respectively.